Yu Sun1, Yuzhu Zheng2, Xiaoyun Yang3, Ke Xie4,5, Chi Du6, Lang He7, Yan Gui8, Jiangping Fu9, Changlin Li10, Huiling Zhang11, Li Zhu12, Jun Bie13, Yi Sun14, Yu Fu15, Yangang Zhou16, Feng Shou17, Yan Wang18, Jiang Zhu19. 1. West China Hospital, Sichuan University, Chengdu, China. 2. The Third People's Hospital of Chengdu, Chengdu, China. 3. Panzhihua University Affiliated Hospital, Panzhihua, China. 4. Sichuan Provincial People's Hospital, Xinjin, China. 5. Jingzhun Hospital, Chengdu, China. 6. Neijiang Second People's Hospital, Neijiang, China. 7. The Fifth People's Hospital of Chengdu, Chengdu, China. 8. Affiliated Hospital of North Sichuan Medical College, Nanchong, China. 9. Dazhou Central Hospital, Dazhou, China. 10. Chengdu First People's Hospital, Chengdu, China. 11. Ziyang First People's Hospital, Ziyang, China. 12. Chengdu Seventh People's Hospital, Chengdu, China. 13. Nanchong Central Hospital, Nanchong, China. 14. Department of Oncology, Western Theater Command Air Force Hospital of PLA., Chengdu, China. 15. Leshan People's Hospital, Leshan, China. 16. Affiliated Hospital of Chengdu Medical College, Chengdu, China. 17. Jianyang People's Hospital, Jianyang, China. 18. The Reproductive Medical Center, Department of Obstetrics and Gynecology, West China Second University Hospital, Sichuan University, Chengdu, China. wangyy1210@163.com. 19. Department of Thoracic Oncology, West China Hospital, Sichuan University, Chengdu, China. zhujiang@wchscu.cn.
Abstract
PURPOSE: Nausea and vomiting are the most painful and feared side effects for patients during chemotherapy. Currently, most studies focus on the occurrence of CINV during the risk phase. We initiated this real-world study to understand the actual occurrence of CINV throughout all phases, to provide a basis to prevent CINV in patients during chemotherapy and improve their quality of life. METHODS: This prospective real-world study was conducted at 17 major cancer centers in Sichuan, China. Cancer patients who were about to receive moderately/highly emetogenic chemotherapy were included in the study. Occurrences of nausea and vomiting were recorded using patient diaries, and physicians are responsible for recording patient clinical data. RESULTS: A total of 1,139 patients were included in this study between August 2018 and April 2019. In this study, the incidence of acute CINV was 55.3%, delayed CINV was 62.3%, and CINV beyond the risk period was 36%. All phases overall, the overall complete control (CC) rate of CINV was 30.1 and 32.1% for highly and moderately emetogenic chemotherapy regimens, respectively. The median CC time for CINV was 7 days, but only 21.5% of these patients used antiemetic regimens according to the NCCN guideline. CONCLUSION: In the real world, the incidence of CINV is high in patients receiving chemotherapy, and nausea and vomiting may occur beyond the risk period; the low level of standardized antiemetic treatment in compliance with the guideline might have been the main reason for unsatisfactory prevention and control of CINV in this study.
PURPOSE:Nausea and vomiting are the most painful and feared side effects for patients during chemotherapy. Currently, most studies focus on the occurrence of CINV during the risk phase. We initiated this real-world study to understand the actual occurrence of CINV throughout all phases, to provide a basis to prevent CINV in patients during chemotherapy and improve their quality of life. METHODS: This prospective real-world study was conducted at 17 major cancer centers in Sichuan, China. Cancerpatients who were about to receive moderately/highly emetogenic chemotherapy were included in the study. Occurrences of nausea and vomiting were recorded using patient diaries, and physicians are responsible for recording patient clinical data. RESULTS: A total of 1,139 patients were included in this study between August 2018 and April 2019. In this study, the incidence of acute CINV was 55.3%, delayed CINV was 62.3%, and CINV beyond the risk period was 36%. All phases overall, the overall complete control (CC) rate of CINV was 30.1 and 32.1% for highly and moderately emetogenic chemotherapy regimens, respectively. The median CC time for CINV was 7 days, but only 21.5% of these patients used antiemetic regimens according to the NCCN guideline. CONCLUSION: In the real world, the incidence of CINV is high in patients receiving chemotherapy, and nausea and vomiting may occur beyond the risk period; the low level of standardized antiemetic treatment in compliance with the guideline might have been the main reason for unsatisfactory prevention and control of CINV in this study.
Authors: M Aapro; A Molassiotis; M Dicato; I Peláez; Á Rodríguez-Lescure; D Pastorelli; L Ma; T Burke; A Gu; P Gascon; F Roila Journal: Ann Oncol Date: 2012-03-06 Impact factor: 32.976
Authors: Henning Burmeister; Stefan Aebi; Cristina Studer; Martin F Fey; Oliver Gautschi Journal: Support Care Cancer Date: 2011-01-14 Impact factor: 3.603
Authors: Sonam Puri; Kelly A Hyland; Kristine Crowe Weiss; Gillian C Bell; Jhanelle E Gray; Richard Kim; Hui-Yi Lin; Aasha I Hoogland; Brian D Gonzalez; Ashley M Nelson; Anita Y Kinney; Stacy M Fischer; Daneng Li; Paul B Jacobsen; Howard L McLeod; Heather S L Jim Journal: Support Care Cancer Date: 2018-03-15 Impact factor: 3.603